The potential of biomarkers in pulmonary arterial hypertension

American Journal of Cardiology

Volumn 110, Issue 6 SUPPL., 2012, Pages S32-S38

  Cracowski, Jean Luc ^a,b,c   Leuchte, Hanno H ^d  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b University Grenoble Alpes   (France)

^c UNIV GRENOBLE ALPES   (France)

^d Neuwittelsbach Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ENDOTHELIN; GROWTH DIFFERENTIATION FACTOR; INTERLEUKIN 2; ISOPROSTANE; NATRIURETIC PEPTIDE RECEPTOR A; NITRIC OXIDE; PROSTAGLANDIN; TROPONIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ASSESSMENT; ENDOTHELIAL DYSFUNCTION; HEART FUNCTION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPONATREMIA; INFLAMMATION; LUNG VASCULAR RESISTANCE; MULTIPLE ORGAN FAILURE; OXIDATIVE STRESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METABOLISM; PULMONARY HYPERTENSION; TREATMENT RESPONSE;

EID: 84865529555     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.06.014     Document Type: Article

References (70)

1. N. Galie, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, J.A. Barbera, M. Beghetti, P. Corris, S. Gaine, J.S. Gibbs Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
2. M.M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, J. Niedermeyer Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur Respir J 26 2005 858 863
3. Biomarkers Definition Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
4. G. Poste Bring on the biomarkers Nature 469 2011 156 157
5. M. Bland An Introduction to Medical Statistics 3rd ed 2000 Oxford University Press Oxford 308 333
6. T. Manolio Novel risk markers and clinical practice N Engl J Med 349 2003 1587 1589
7. J.H. Ware The limitations of risk factors as prognostic tools N Engl J Med 355 2006 2615 2617
8. M.A. Daubert, A. Jeremias The utility of troponin measurement to detect myocardial infarction: review of the current findings Vasc Health Risk Manag 6 2010 691 699
9. H.W. Farber, J. Loscalzo Pulmonary arterial hypertension N Engl J Med 351 2004 1655 1665
10. G. Warwick, P.S. Thomas, D.H. Yates Biomarkers in pulmonary hypertension Eur Respir J 32 2008 503 512
11. S. Rafeq, A.M. Shah, I.R. Preston Biomarkers in pulmonary arterial hypertension Int J Clin Pract Suppl 162 2009 36 41
12. G.A. Heresi Clinical perspective: biomarkers in pulmonary arterial hypertension Int J Clin Pract Suppl 169 2011 5 7
13. B.W. Christman, C.D. McPherson, J.H. Newman, G.A. King, G.R. Bernard, B.M. Groves, J.E. Loyd An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N Engl J Med 327 1992 70 75
14. A. Giaid, D. Saleh Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension N Engl J Med 333 1995 214 221
15. N.A. Mason, D.R. Springall, M. Burke, J. Pollock, G. Mikhail, M.H. Yacoub, J.M. Polak High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension J Pathol 185 1998 313 318
16. S. Pullamsetti, L. Kiss, H.A. Ghofrani, R. Voswinckel, P. Haredza, W. Klepetko, C. Aigner, L. Fink, J.P. Muyal, N. Weissmann Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension FASEB J 19 2005 1175 1177
17. J.T. Kielstein, S.M. Bode-Boger, G. Hesse, J. Martens-Lobenhoffer, A. Takacs, D. Fliser, M.M. Hoeper Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension Arterioscler Thromb Vasc Biol 25 2005 1414 1418
18. F.T. Kaneko, A.C. Arroliga, R.A. Dweik, S.A. Comhair, D. Laskowski, R. Oppedisano, M.J. Thomassen, S.C. Erzurum Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension Am J Respir Crit Care Med 158 1998 917 923
19. M.S. Riley, J. Porszasz, J. Miranda, M.P. Engelen, B. Brundage, K. Wasserman Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis Chest 111 1997 44 50
20. I.A. Forrest, T. Small, P.A. Corris Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls Clin Sci (Lond) 97 1999 99 102
21. R.E. Girgis, H.C. Champion, G.B. Diette, R.A. Johns, S. Permutt, J.T. Sylvester Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy Am J Respir Crit Care Med 172 2005 352 357
22. M. Ozkan, R.A. Dweik, D. Laskowski, A.C. Arroliga, S.C. Erzurum High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy Lung 179 2001 233 243
23. C. Rubens, R. Ewert, M. Halank, R. Wensel, H.D. Orzechowski, H.P. Schultheiss, G. Hoeffken Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension Chest 120 2001 1562 1569
24. D. Montani, R. Souza, C. Binkert, W. Fischli, G. Simonneau, M. Clozel, M. Humbert Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension Chest 131 2007 101 108
25. S.M. Kawut, E.M. Horn, K.K. Berekashvili, A.C. Widlitz, E.B. Rosenzweig, R.J. Barst von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension Chest 128 2005 2355 2362
26. A.A. Lopes, N.Y. Maeda Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension Chest 114 1998 1276 1282
27. R. Bowers, C. Cool, R.C. Murphy, R.M. Tuder, M.W. Hopken, S.C. Flores, N.F. Voelkel Oxidative stress in severe pulmonary hypertension Am J Respir Crit Care Med 169 2004 764 769
28. V.G. DeMarco, J. Habibi, A.T. Whaley-Connell, R.I. Schneider, R.L. Heller, J.P. Bosanquet, M.R. Hayden, K. Delcour, S.A. Cooper, B.T. Andresen, J.R. Sowers, K.C. Dellsperger Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2) 27 rat Am J Physiol Heart Circ Physiol 294 2008 H2659 H2668
29. M. Humbert, G. Monti, F. Brenot, O. Sitbon, A. Portier, L. Grangeot-Keros, P. Duroux, P. Galanaud, G. Simonneau, D. Emilie Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension Am J Respir Crit Care Med 151 1995 1628 1631
30. T. Itoh, N. Nagaya, H. Ishibashi-Ueda, S. Kyotani, H. Oya, F. Sakamaki, H. Kimura, N. Nakanishi Increased plasma monocyte chemoattractant protein1 level in idiopathic pulmonary arterial hypertension Respirology 11 2006 158 163
31. E. Soon, A.M. Holmes, C.M. Treacy, N.J. Doughty, L. Southgate, R.D. Machado, R.C. Trembath, S. Jennings, L. Barker, P. Nicklin Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension Circulation 122 2010 920 927
32. J.M. Lorenzen, N. Nickel, R. Kramer, H. Golpon, V. Westerkamp, K.M. Olsson, H. Haller, M.M. Hoeper Osteopontin in patients with idiopathic pulmonary hypertension Chest 139 2011 1010 1017
33. R. Quarck, T. Nawrot, B. Meyns, M. Delcroix C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension J Am Coll Cardiol 53 2009 1211 1218
34. N. Nickel, T. Kempf, H. Tapken, J. Tongers, F. Laenger, U. Lehmann, H. Golpon, K. Olsson, M.R. Wilkins, J.S. Gibbs, M.M. Hoeper, K.C. Wollert Growth differentiation factor15 in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 178 2008 534 541
35. J.L. Cracowski, C. Cracowski, G. Bessard, J.L. Pepin, J. Bessard, C. Schwebel, F. Stanke-Labesque, C. Pison Increased lipid peroxidation in patients with pulmonary hypertension Am J Respir Crit Care Med 164 2001 1038 1042
36. I.M. Robbins, J.D. Morrow, B.W. Christman Oxidant stress but not thromboxane decreases with epoprostenol therapy Free Radic Biol Med 38 2005 568 574
37. R.M. Tuder, N.F. Voelkel Pulmonary hypertension and inflammation J Lab Clin Med 132 1998 16 24
38. G.A. Heresi, M. Aytekin, J. Newman, R.A. Dweik CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival Lung 188 2010 191 197
39. J.L. Cracowski, B. Degano, F. Chabot, J. Lebarre, E. Schwedheim, D. Monneret, L. Iuliano, C. Schwebel, A. Chaouat, M. Reynaud-Gaubert Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension Chest 2012 Mar 8 [Epub ahead of print]
40. K. Maeda, T. Tsutamoto, A. Wada, T. Hisanaga, M. Kinoshita Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction Am Heart J 135 1998 825 832
41. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, A.M. Richards Treatment of heart failure guided by plasma aminoterminal BNP (N-) concentration Lancet 355 2000 1126 1130
42. R. Wiedemann, H.A. Ghofrani, N. Weissmann, R. Schermuly, K. Quanz, F. Grimminger, W. Seeger, H. Olschewski Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation J Am Coll Cardiol 38 2001 1130 1136
43. H.H. Leuchte, R.A. Baumgartner, M.E. Nounou, M. Vogeser, C. Neurohr, M. Trautnitz, J. Behr Brain natriuretic peptide is a prognostic parameter in chronic lung disease Am J Respir Crit Care Med 173 2006 744 750
44. H.H. Leuchte, C. Neurohr, R. Baumgartner, M. Holzapfel, W. Giehrl, M. Vogeser, J. Behr Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension Am J Respir Crit Care Med 170 2004 360 365
45. H.H. Leuchte, M. Holzapfel, R.A. Baumgartner, I. Ding, C. Neurohr, M. Vogeser, T. Kolbe, M. Schwaiblmair, J. Behr Clinical significance of brain natriuretic peptide in primary pulmonary hypertension J Am Coll Cardiol 43 2004 764 770
46. N. Nagaya, T. Nishikimi, Y. Okano, M. Uematsu, T. Satoh, S. Kyotani, S. Kuribayashi, S. Hamada, M. Kakishita, N. Nakanishi Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension J Am Coll Cardiol 31 1998 202 208
47. H.H. Leuchte, M. Holzapfel, R.A. Baumgartner, C. Neurohr, M. Vogeser, J. Behr Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension Chest 128 2005 2368 2374
48. N. Nagaya, T. Nishikimi, M. Uematsu, T. Satoh, S. Kyotani, F. Sakamaki, M. Kakishita, K. Fukushima, Y. Okano, N. Nakanishi, K. Miyatake, K. Kangawa Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension Circulation 102 2000 865 870
49. A. Fijalkowska, M. Kurzyna, A. Torbicki, G. Szewczyk, M. Florczyk, P. Pruszczyk, M. Szturmowicz Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension Chest 129 2006 1313 1321
50. H.H. Leuchte, M. El Nounou, J.C. Tuerpe, B. Hartmann, R.A. Baumgartner, M. Vogeser, O. Muehling, J. Behr N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension Chest 131 2007 402 409
51. N. Gali, H. Olschewski, R.J. Oudiz, F. Torres, A. Frost, H.A. Ghofrani, D.B. Badesch, M.D. McGoon, V.V. McLaughlin, E.B. Roecker Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 Circulation 117 2008 3010 3019
52. N. Gali, L. Rubin, M. Hoeper, P. Jansa, H. Al-Hiti, G. Meyer, E. Chiossi, A. Kusic-Pajic, G. Simonneau Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100
53. X. Jais, A.M. D'Armini, P. Jansa, A. Torbicki, M. Delcroix, H.A. Ghofrani, M.M. Hoeper, I.M. Lang, E. Mayer, J. Pepke-Zaba Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial J Am Coll Cardiol 52 2008 2127 2134
54. M.M. Redfield, R.J. Rodeheffer, S.J. Jacobsen, D.W. Mahoney, K.R. Bailey, J.C. Burnett Plasma brain natriuretic peptide concentration: impact of age and gender J Am Coll Cardiol 40 2002 976 982
55. A. Torbicki, M. Kurzyna, P. Kuca, A. Fijalkowska, J. Sikora, M. Florczyk, P. Pruszczyk, J. Burakowski, L. Wawrzynska Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension Circulation 108 2003 844 848
56. R.H. Christenson, D. Phillips Sensitive and high sensitivity next generation cardiac troponin assays: more than just a name Pathology 43 2011 213 219
57. A. Filusch, E. Giannitsis, H.A. Katus, F.J. Meyer High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension Clin Sci (Lond) 119 2010 207 213
58. G.A. Heresi, W.H. Tang, M. Aytekin, J. Hammel, S.L. Hazen, R.A. Dweik Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension Eur Respir J 39 2012 939 944
59. P.R. Forfia, S.C. Mathai, M.R. Fisher, T. Housten-Harris, A.R. Hemnes, H.C. Champion, R.E. Girgis, P.M. Hassoun Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension Am J Respir Crit Care Med 177 2008 1364 1369
60. B. Sztrymf, R. Souza, L. Bertoletti, X. Jais, O. Sitbon, L.C. Price, G. Simonneau, M. Humbert Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension Eur Respir J 35 2010 1286 1293
61. J.D. Myers, J.B. Hickam An estimation of hepatic blood flow and splanchnic oxygen consumption in heart failure J Clin Invest 27 1948 620 627
62. S.M. Richman, A.J. Delman, D. Crob Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes Am J Med 30 1961 211 255
63. Y. Takeda, Y. Takeda, S. Tomimoto, R. Tami, H. Narita, G. Kimura Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension BMC Pulm Med 10 2010 22
64. R.L. Benza, D.P. Miller, M. Gomberg-Maitland, R.P. Frantz, A.J. Foreman, C.S. Coffey, A. Frost, R.J. Barst, D.B. Badesch, C.G. Elliott, T.G. Liou, M.D. McGoon Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2011 164 172
65. S.J. Shah, T. Thenappan, S. Rich, L. Tian, S.L. Archer, M. Gomberg-Maitland Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension Circulation 117 2008 2475 2483
66. N. Nagaya, M. Uematsu, T. Satoh, S. Kyotani, F. Sakamaki, N. Nakanishi, M. Yamagishi, T. Kunieda, K. Miyatake Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension Am J Respir Crit Care Med 160 1999 487 492
67. G.A. Heresi, M. Aytekin, J. Newman, J. DiDonato, R.A. Dweik Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension Am J Respir Crit Care Med 182 2010 661 668
68. H.J. Issaq, T.D. Veenstra, T.P. Conrads, D. Felschow The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification Biochem Biophys Res Commun 292 2002 587 592
69. V.B. Abdul-Salam, G.A. Paul, J.O. Ali, S.R. Gibbs, D. Rahman, G.W. Taylor, M.R. Wilkins, R.J. Edwards Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension Proteomics 6 2006 2286 2294
70. B.O. Meyrick, D.B. Friedman, D.D. Billheimer, J.D. Cogan, M.A. Prince, J.A. Phillips, J.E. Loyd Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension Am J Respir Crit Care Med 177 2008 99 107